Medical Policy
Cardiovascular Risk Panels

Table of Contents
• Policy: Commercial
• Authorization Information
• Coding Information

Description
• Information Pertaining to All Policies
• Policy History
• References

Policy Number: 664
BCBSA Reference Number: 2.04.100 (For Plan internal use only)
NCD/LCD: N/A

Related Policies
• Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic Disease, #016
• Measurement of Lipoprotein-Associated Phospholipase A2 in the Assessment of Cardiovascular Risk, #558
• Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease, #283
• Ultrasonographic Measurement of Carotid Intima-Medial Thickness as an Assessment of Subclinical Atherosclerosis, #547

Policy
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity
Medicare HMO BlueSM and Medicare PPO BlueSM Members

Cardiovascular disease risk panels, consisting of multiple individual biomarkers intended to assess cardiac risk, are Investigational.

Prior Authorization Information
Inpatient
• For services described in this policy, precertification/preauthorization is required for all products if the procedure is performed inpatient.

Outpatient
• For services described in this policy, see below for products where prior authorization might be required if the procedure is performed outpatient.

<table>
<thead>
<tr>
<th>Commercial Managed Care (HMO and POS)</th>
<th>Outpatient</th>
</tr>
</thead>
<tbody>
<tr>
<td>This is not a covered service.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Commercial PPO and Indemnity</th>
<th>Outpatient</th>
</tr>
</thead>
<tbody>
<tr>
<td>This is not a covered service.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medicare HMO BlueSM</th>
<th>Outpatient</th>
</tr>
</thead>
<tbody>
<tr>
<td>This is not a covered service.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medicare PPO BlueSM</th>
<th>Outpatient</th>
</tr>
</thead>
<tbody>
<tr>
<td>This is not a covered service.</td>
<td></td>
</tr>
</tbody>
</table>
CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

CPT Codes
No specific CPT codes

Description
Cardiovascular Disease
Cardiovascular disease (CVD) remains the single largest cause of morbidity and mortality in the developed world. Mortality from CVD has accounted for 1 in 4 deaths in the United States, and there are numerous socio-economic factors that affect CVD mortality rates. Lower-income, race, age, and behavioral factors all have a significant impact on health outcome disparities associated with CVD.

As a result, accurate prediction of CVD risk is a component of medical care that has the potential to focus on and direct preventive and diagnostic activities. Current methods of risk prediction in use in general clinical care are not highly accurate and, as a result, there is a potential unmet need for improved risk prediction instruments.

Risk Assessment
Components of CVD risk include family history, cigarette smoking, hypertension, and lifestyle factors such as diet and exercise. Also, numerous laboratory tests have been associated with CVD risk, most prominently lipids such as low-density lipoprotein (LDL) and high-density lipoprotein (HDL). These clinical and lipid factors are often combined into simple risk prediction instruments, such as the Framingham Risk Score. The Framingham Risk Score provides an estimate of the 10-year risk for developing cardiac disease and is currently used in clinical care to determine the aggressiveness of risk factor intervention, such as the decision to treat hyperlipidemia with statins.

Many additional biomarkers, genetic factors, and radiologic measures have been associated with an increased risk of CVD. Over 100 emerging risk factors have been proposed as useful for refining estimates of CVD risk. Some general categories of these potential risk factors are as follows:

- **Lipid markers.** In addition to LDL and HDL, other lipid markers may have predictive ability, including the apolipoproteins, lipoprotein (a) (Lp[a]), lipid subfractions, and/or other measures.
- **Inflammatory markers.** Many measures of inflammation have been linked to the likelihood of CVD. High-sensitivity C-reactive protein (hs-CRP) is an example of an inflammatory marker; others include fibrinogen, interleukins, and tumor necrosis factor.
- **Metabolic syndrome biomarkers.** Measures associated with metabolic syndromes, such as specific dyslipidemic profiles or serum insulin levels, have been associated with an increased risk of CVD.
- **Genetic markers.** A number of variants associated with increased thrombosis risk, such as the 5,10-methylene tetrahydrofolate reductase (MTHFR) variant or the prothrombin gene variants, have been associated with increased CVD risk. Also, numerous single nucleotide variants have been associated with CVD in large genome-wide studies.

Risk Panel Testing
Cardiovascular disease risk panels may contain measures from 1 or all of the previous categories and may include other measures not previously listed such as radiologic markers (carotid medial thickness, coronary artery calcium score). Some CVD risk panels are relatively limited, including a few markers in addition to standard lipids. Others include a wide variety of potential risk factors from a number of different categories, often including both genetic and nongenetic risk factors. Other panels are composed entirely of genetic markers.
Some examples of commercially available CVD risk panels are as follows:

- **CV Health Plus Genomics™ Panel (Genova Diagnostics):** apolipoprotein (apo) E; prothrombin; factor V Leiden; fibrinogen; HDL; HDL size; HDL particle number; homocysteine; LDL; LDL size; LDL particle number; Lp(a); lipoprotein-associated phospholipase A2 (Lp-PLA2); MTHFR gene; triglycerides; very-low-density lipoprotein (VLDL); VLDL size; vitamin D; hs-CRP.

- **CV Health Plus™ Panel (Genova Diagnostics):** fibrinogen; HDL; HDL size; HDL particle number; homocysteine; LDL; LDL size; LDL particle number; lipid panel; Lp(a); Lp-PLA2; triglycerides; VLDL; VLDL size; vitamin D; hs-CRP.

- **CVD Inflammatory Profile (Cleveland HeartLab):** hs-CRP, urinary microalbumin, myeloperoxidase, Lp-PLA2, F2 isoprostanes.

- **Applied Genetics Cardiac Panel:** genetic variants associated with coronary artery disease: cytochrome p450 variants associated with the metabolism of clopidogrel, ticagrelor, warfarin, b-blockers, rivaroxaban, prasugrel (2C19, 2C9/VKORC1, 2D6, 3A4/3A5), factor V Leiden, prothrombin gene, MTHFR gene, APOE gene.

- **Genetiks Genetic Diagnosis and Research Center Cardiovascular Risk Panel:** factor V Leiden, factor V R2, prothrombin gene, factor XIII, fibrinogen-455, plasminogen activator inhibitor-1, platelet glycoprotein (GP) IIIa variant human platelet antigen (HPA)-1 (PLA1/2), MTHFR gene, angiotensin-converting enzyme insertion/deletion, apo B, apo E.

In addition to panels that are specifically focused on CVD risk, a number of commercially available panels include markers associated with cardiovascular health, along with a range of other markers that have been associated with inflammation, thyroid disorders and other hormonal deficiencies, and other disorders. An example of these panels is:

- **WellnessFX Premium (WellnessFX):** total cholesterol, HDL, LDL, triglycerides, apo AI, apo B, Lp(a), Lp-PLA2, omega-3 fatty acids, free fatty acids, lipid particle numbers, lipid particle sizes, blood urea nitrogen/creatinine, aspartate aminotransferase and alanine aminotransferase, total bilirubin, albumin, total protein, dehydroepiandrosterone, free testosterone, total testosterone, estradiol, sex hormone binding globulin, cortisol, insulin-like growth factor 1, insulin, glucose, hemoglobin A1c, total T4, T3 uptake, free T4 index, thyroid-stimulating hormone, total T3, free T3, reverse T3, free T4, hs-CRP, fibrinogen, homocysteine, complete blood count with differential, calcium, electrolytes, bicarbonate, ferritin, total iron-binding capacity, vitamin B12, red blood cell magnesium, 25-hydroxy vitamin D, progesterone, follicle-stimulating hormone, luteinizing hormone.

**Summary**

Cardiovascular risk panels refer to different combinations of cardiac markers that are intended to evaluate the risk of cardiovascular disease (CVD). There are numerous commercially available risk panels that include different combinations of lipids, noncardiac biomarkers, measures of inflammation, metabolic parameters, and/or genetic markers. Risk panels report the results of multiple individual tests, as distinguished from quantitative risk scores that combine the results of multiple markers into a single score.

**Summary of Evidence**

For individuals who have risk factors for CVD who receive CVD risk panels, the evidence includes multiple cohorts and case-control studies and systematic reviews of these studies. Relevant outcomes are test validity, other test performance measures, change in disease status, and morbid events. The available evidence from cohort and case-control studies indicates that many of the individual risk factors included in CVD risk panels are associated with an increased risk of CVD. However, it is not clear how the results of individual risk factors impact management changes, so it is also uncertain how the panels will impact management decisions. Given the lack of evidence for the clinical utility of any individual risk factor beyond simple lipid measures, it is unlikely that the use of CVD risk panels improves outcomes. Studies that have evaluated the clinical validity of panels of multiple markers have not assessed management changes that would occur as a result of testing or demonstrated improvements in outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
Policy History

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/2023</td>
<td>Annual policy review. Description, summary, and references updated. Policy statements unchanged.</td>
</tr>
<tr>
<td>2/2022</td>
<td>Annual policy review. Description, summary, and references updated. Policy statements unchanged.</td>
</tr>
<tr>
<td>2/2021</td>
<td>Annual policy review. Description, summary, and references updated. Policy statements unchanged.</td>
</tr>
<tr>
<td>1/2020</td>
<td>Annual policy review. Description, summary, and references updated. Policy statements unchanged.</td>
</tr>
<tr>
<td>1/2016</td>
<td>Annual policy review. New references added.</td>
</tr>
<tr>
<td>12/2014</td>
<td>Annual policy review. New references added.</td>
</tr>
</tbody>
</table>

Information Pertaining to All Blue Cross Blue Shield Medical Policies
Click on any of the following terms to access the relevant information:
- Medical Policy Terms of Use
- Managed Care Guidelines
- Indemnity/PPO Guidelines
- Clinical Exception Process
- Medical Technology Assessment Guidelines

References


the American Heart Association and American College of Cardiology. Circulation. Jun 18 2019; 139(25): e1162-e1177. PMID 30586766